Abstract 113P
Background
Chemotherapy has a good success rate in colorectal cancer (CRC); however, recurrence of CRC is still frequent due to acquired drug resistance. Dicer, one of the key enzymes of the microRNA (miRNA) biogenesis pathway, may be involved in chemoresistance through regulating the expression of miRNAs. Until now, the role of Dicer in regulating chemoresistance is still unclear.
Methods
Oxaliplatin- or 5’FU-resistant cell lines were established to investigate the molecular mechanism of chemoresistance. Western blot was performed to detect the expression of Dicer; next-generation sequencing (NGS) and cDNA array were performed to identify the alternative expression of miRNAs and mRNAs; and RT-qPCR or TaqMan PCR was used to validate the expression of potential miRNAs or mRNAs. Functional characterization of drug-resistant cells was performed by cell proliferation, colony formation, sphere formation, migration and invasive assays.
Results
From the TCGA database, the expression level of Dicer mRNA is increased in colorectal cancer; the level of Dicer protein is increased in oxaliplatin- or 5’FU-resistant cell lines. The drug resistant cells possess increased abilities in cell migration, invasion and sphere formation. Knocked-down expression of Dicer can enhance the drug sensitivity in drug resistant cells; in contrast, overexpression of Dicer increases drug resistance in parental drug sensitive cells. By next-generation sequencing and cDNA array, we found that the expression of a set of miRNAs and their downstream mRNAs is changed in oxaliplatin resistant cells. Dicer overexpression enhances the expression of those miRNAs and mRNAs in drug sensitive parental cells. Clinical evaluation further confirmed the increased expression of those miRNAs in the plasma of CRC patients is positively correlated with a poor response to oxaliplatin. In addition, NF-kB and Wnt pathways were found to be activated in drug resistant cells.
Conclusions
Our results suggest that those miRNAs may act as biomarkers to predict oxaliplatin response in colorectal cancer by detecting their plasma miRNAs. The molecular mechanism of those miRNAs in regulating the drug response is currently under our investigation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Ministry of Science and Technology.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
490P - Outcomes of sequential epidermal growth factor receptor tyrosine (EGFR) tyrosine kinase inhibitor (TKI) therapy in patients with advanced non-small cell lung carcinoma (NSCLC)- a real-world institutional experience
Presenter: Yvonne Ang
Session: Poster display session
Resources:
Abstract
498P - An observational retrospective study to evaluate the incidence of acquired EGFR T790M resistance in NSCLC patients with EGFR mutation following progression after at least one prior EGFR TKI treatment in Taiwan: ARISE study
Presenter: Shang-gin Wu
Session: Poster display session
Resources:
Abstract
501P - Clinical characteristics and efficacy in non-small cell lung cancer patients with EGFR exon 20 insertion and EGFR amplification
Presenter: Xin Gao
Session: Poster display session
Resources:
Abstract
502P - Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced non-small cell lung cancer with uncommon mutations: A multicenter observational study
Presenter: Masaki Kanazu
Session: Poster display session
Resources:
Abstract
482P - Interim analysis from a phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC
Presenter: Filippo De Marinis
Session: Poster display session
Resources:
Abstract
483P - A phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients with EGFR mutation-positive NSCLC: A biomarker analysis
Presenter: Rafael Rosell
Session: Poster display session
Resources:
Abstract
484P - Activity of afatinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC and baseline brain metastases: Pooled analysis of three large phase IIIb trials
Presenter: Maya Gottfried
Session: Poster display session
Resources:
Abstract
491P - Clinical outcomes of leptomeningeal metastases in EGFR-mutant lung adenocarcinoma
Presenter: Chia-I Shen
Session: Poster display session
Resources:
Abstract
510P - Paclitaxel as continuation maintenance therapy in patients with advanced non-small cell lung cancer
Presenter: Suzy Gohar
Session: Poster display session
Resources:
Abstract
496P - Higher osimertinib introduction rate achieved by multiple repeated re-biopsy after acquired resistance to first/second generation EGFR-TKIs
Presenter: Taira Ninomaru
Session: Poster display session
Resources:
Abstract